CytomX Therapeutics CTMX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $28.83M-39.4% | $12.67M-66.7% | $34.19M-15.8% | $49.04M+13.4% | $47.6M+31.6% | ||
| $317.88M+885% | $124.39M+98.8% | $109.44M+42.1% | $109.05M+16.1% | $32.28M-71.7% | ||
| $1.53M+48.5% | $1.53M+48.7% | $1.03M+0.1% | $1.03M+12.1% | $1.03M+12.1% | ||
| $646K-67.0% | $2.01M-35.1% | $1.63M-51.4% | $1.87M-32.6% | $1.96M-85.2% | ||
| $5.74M+20.0% | $4.86M+35.7% | $3.96M+22.3% | $4.67M+49.4% | $4.79M+26.4% | ||
| $353.1M+308% | $143.92M+34.1% | $149.22M+20.2% | $164.62M+15.1% | $86.63M-48.2% | ||
| $1.09M-51.1% | $1.3M-47.1% | $1.72M-41.5% | $1.95M-41.3% | $2.23M-37.5% | ||
| $2.26M-67.9% | $3.4M-58.3% | $4.81M-47.6% | $5.95M-41.8% | $7.06M-37.2% | ||
| $949K0.0% | $949K0.0% | $949K0.0% | $949K0.0% | $949K0.0% | ||
| $401K-26.7% | $438K-24.9% | $474K-23.5% | $510K-22.3% | $547K-21.1% | ||
| $31K-49.2% | $31K-53.0% | $51K-27.1% | $56K-26.3% | $61K-23.8% | ||
| $359.36M+265% | $151.57M+25.7% | $158.25M+13.9% | $175.06M+9.9% | $98.5M-46.7% | ||
| $1.37M+396% | $1.3M+19.6% | $646K-54.6% | $227K-62.8% | $276K-85.9% | ||
| $11.92M+4.5% | $14.2M+15.1% | $12.41M-25.9% | $11.5M-15.5% | $11.41M-19.8% | ||
| $17.88M-46.2% | $26.88M-60.0% | $22.38M-76.7% | $22.05M-82.2% | $33.23M-73.1% | ||
| $2.86M-46.0% | $4.24M-17.6% | $5.6M+11.9% | $5.44M+12.0% | $5.29M+12.0% | ||
| $979K-94.0% | $1.59M-94.1% | $5.54M-83.5% | $10.24M-72.1% | $16.21M-72.9% | ||
| $34.02M-32.2% | $46.62M-45.7% | $41.03M-65.6% | $39.22M-72.5% | $50.2M-65.3% | ||
| $4.41M+5.6% | $4.35M+5.8% | $4.3M+6.1% | $4.24M+6.2% | $4.18M+6.0% | ||
| $39.41M-46.3% | $52.56M-56.6% | $50.87M-68.7% | $55.15M-71.0% | $73.45M-66.1% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $2K+100% | $2K+100% | $2K+100% | $2K+100% | $1K0.0% | ||
| $1.05B+51.5% | $810.84M+17.3% | $789.72M+15.0% | $788.08M+15.1% | $693.1M+2.2% | ||
| -$730.2M-9.3% | -$711.95M-2.9% | -$682.44M+3.9% | -$668.21M+6.7% | -$668.05M+5.9% | ||
| $102K+10,300% | $111K+311% | $104K+160% | $33K+925% | -$1K+90.0% | ||
| $319.94M+1,177% | $99.01M+21,812% | $107.39M+558% | $119.91M+484% | $25.05M+179% | ||
| $359.36M+265% | $151.57M+25.7% | $158.25M+13.9% | $175.06M+9.9% | $98.5M-46.7% | ||
| $317.88M+885% | $124.39M+98.8% | $109.44M+42.1% | $109.05M+16.1% | $32.28M-71.7% | ||
| $31K-49.2% | $31K-53.0% | $51K-27.1% | $56K-26.3% | $61K-23.8% | ||
| $401K-26.7% | $438K-24.9% | $474K-23.5% | $510K-22.3% | $547K-21.1% | ||
| $401K-26.7% | $438K-24.9% | $474K-23.5% | $510K-22.3% | $547K-21.1% | ||
| $401K-26.7% | $438K-24.9% | $474K-23.5% | $510K-22.3% | $547K-21.1% | ||
| $401K-26.7% | $438K-24.9% | $474K-23.5% | $510K-22.3% | $547K-21.1% | ||
| $2.26M-67.9% | $3.4M-58.3% | $4.81M-47.6% | $5.95M-41.8% | $7.06M-37.2% | ||
| $2.26M-67.9% | $3.4M-58.3% | $4.81M-47.6% | $5.95M-41.8% | $7.06M-37.2% | ||
| $31K-49.2% | $31K-53.0% | $51K-27.1% | $56K-26.3% | $61K-23.8% | ||
| $2.26M-67.9% | $3.4M-58.3% | $4.81M-47.6% | $5.95M-41.8% | $7.06M-37.2% | ||
| $31K-49.2% | $31K-53.0% | $51K-27.1% | $56K-26.3% | $61K-23.8% | ||
| $979K-94.0% | $1.59M-94.1% | $5.54M-83.5% | $10.24M-72.1% | $16.21M-72.9% | ||
| $11.92M+4.5% | $14.2M+15.1% | $12.41M-25.9% | $11.5M-15.5% | $11.41M-19.8% | ||
| $11.92M+4.5% | $14.2M+15.1% | $12.41M-25.9% | $11.5M-15.5% | $11.41M-19.8% | ||
| $979K-94.0% | $1.59M-94.1% | $5.54M-83.5% | $10.24M-72.1% | $16.21M-72.9% | ||
| $979K-94.0% | $1.59M-94.1% | $5.54M-83.5% | $10.24M-72.1% | $16.21M-72.9% | ||
| $2.86M-65.0% | $4.24M-54.8% | $5.6M-47.2% | $6.89M-41.4% | $8.15M-36.7% | ||
| $2K+100% | $2K+100% | $2K+100% | $2K+100% | $1K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $401K-26.7% | $438K-24.9% | $474K-23.5% | $510K-22.3% | $547K-21.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are CytomX Therapeutics's total assets?
- CytomX Therapeutics (CTMX) holds $359.4M in total assets, up 264.8% year over year.
- How much debt does CytomX Therapeutics have?
- CytomX Therapeutics carries $2.9M in total debt against $319.9M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does CytomX Therapeutics have?
- CytomX Therapeutics holds $28.8M in cash and equivalents.
- Can CytomX Therapeutics cover its short-term obligations?
- Its current ratio is 10.38 — current assets exceed current liabilities.
- Where does CytomX Therapeutics's balance sheet data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
